Medicare’s $50 GLP-1 Bridge: Who Qualifies and What It Excludes

Medicare’s new GLP-1 Bridge began nationwide on July 1, 2026, giving some beneficiaries a separate route to selected weight-management drugs for a $50 monthly copay. The temporary demonstration is scheduled to run through December 31, 2027, and it is not a permanent Medicare benefit.

The program is narrower than the headline price suggests. Eligibility depends on Medicare drug coverage, clinical criteria, prior authorization and the exact medicine and formulation prescribed.

Who may qualify

Generally, a beneficiary must be at least 18 and enrolled in qualifying Medicare drug coverage. Eligible coverage can include a standalone Part D plan, a Medicare Advantage plan with drug coverage, a Special Needs Plan, an employer or union group waiver plan, or the Limited Income Newly Eligible Transition program.

The clinical rules depend on body mass index, or BMI, at the time GLP-1 therapy begins:

• BMI of 35 or higher, or
• BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a-or-higher chronic kidney disease, or
• BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

Having obesity alone does not guarantee access. A provider must prescribe the medicine and submit a prior-authorization request. The provider must also attest that the drug is being used to reduce excess body weight or maintain weight reduction alongside an ongoing lifestyle program involving structured nutrition and physical activity.

Which medicines are included

CMS currently lists Foundayo, all formulations of Wegovy and the KwikPen formulation of Zepbound for the Bridge. Single-dose Zepbound pens and vials are excluded.

That product-specific rule matters at the pharmacy counter. A prescription for a different formulation should not be assumed to qualify simply because the same brand appears on the covered-product list. CMS says the covered-product list may be updated during the demonstration.

The $50 copay operates outside Part D

The Bridge uses a separate payment structure rather than the ordinary Part D benefit. The Part D deductible does not apply to the $50 monthly copay, and no part of the payment counts toward a beneficiary’s true out-of-pocket, or TrOOP, costs.

Medicare’s Low-Income Subsidy, commonly called Extra Help, also does not reduce or absorb the Bridge copay. Beneficiaries should therefore budget for the full $50 each month if they are approved.

Because the payment sits outside the normal Part D flow, it does not help a beneficiary reach the Part D out-of-pocket threshold. CMS also says Bridge claims do not coordinate benefits with other payers, and coupons or discount programs cannot be applied to Bridge claims.

Who may be routed elsewhere

People who already receive a GLP-1 through their Part D plan are not eligible to use the Bridge for the same route. CMS says beneficiaries with a prescription for a GLP-1 drug for an indication covered by Part D should continue obtaining that medicine through their Part D plan.

Those indications include type 2 diabetes, moderate-to-severe obstructive sleep apnea and noncirrhotic metabolic dysfunction-associated steatohepatitis, commonly called MASH, with moderate to advanced liver scarring. The Bridge is for weight reduction or weight maintenance; it should not be confused with Part D coverage for those other indications.

CMS is using Humana as the central processor for 2026. The processor handles prior authorization, claims adjudication and payment to pharmacies, so pharmacies may need to follow Bridge-specific procedures even when a beneficiary otherwise has Medicare drug coverage.

How broad could the program become?

An analysis by KFF estimated that about 3.8 million Medicare Part D enrollees could potentially meet the program’s full eligibility conditions, based on 2023 claims data. That is an estimate, not a current enrollment count or a confirmed number of participants.

KFF also modeled possible federal costs under different assumptions about participation and monthly prescription use. Depending on those assumptions, the analysis estimated federal costs ranging from $1.3 billion to $10 billion over the program period. Those figures are scenarios, not a final cost estimate or a forecast of actual spending.

What beneficiaries should check

Before applying, confirm that you have qualifying Medicare drug coverage and ask a clinician to review your BMI, related conditions and the intended use of the prescription. Expect prior authorization and provider certification.

Ask the pharmacy to verify the exact product and formulation. If a GLP-1 is already covered through your Part D plan, that existing coverage—not the Bridge—may be the applicable route. Medicare.gov says an approved prior authorization can remain valid, including for refills and dose changes, through December 31, 2027 unless the beneficiary changes GLP-1 drugs.

CMS directs beneficiaries to Medicare.gov’s GLP-1 Bridge information and 1-800-MEDICARE for eligibility, pharmacy and coverage questions.

Sources

• CMS: Medicare GLP-1 Bridge
• Medicare.gov: Weight loss drugs
• KFF: Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program

Look for updates to this story

Related News

• Medicaid Work-Rule Fight Moves to State Implementation
• GAO finds process failures in federal watchdog oversight panel
• Supreme Court case could test religious schools’ access to public preschool funds
• Immigration courts are moving faster as deportation orders rise